Local News

Losses Increase At Inspire

Posted August 9, 2006

— Quarterly losses for

Inspire Pharmaceuticals

(Nasdaq: ISPH) increased to $5.4 million, up $600,000 from a year ago, despite a surge in revenues in the second quarter, the company said Tuesday.

Expenses increased to $20 million from $15.3 million in 2005 due to research and development as well as administrative costs, the company said.

Revenues climbed to $13.4 million from $9.6 million based in large part on co-promotion and sale of the drugs Restasis and Elestat.


Please with your WRAL.com account to comment on this story. You also will need a Facebook account to comment.

Oldest First
View all